拉科酰胺结构式
|
常用名 | 拉科酰胺 | 英文名 | Lacosamide |
---|---|---|---|---|
CAS号 | 175481-36-4 | 分子量 | 250.294 | |
密度 | 1.1±0.1 g/cm3 | 沸点 | 536.4±50.0 °C at 760 mmHg | |
分子式 | C13H18N2O3 | 熔点 | 141-143?C | |
MSDS | N/A | 闪点 | 278.2±30.1 °C | |
符号 |
GHS02, GHS07 |
信号词 | Danger |
拉科酰胺用途Lacosamide (Vimpat; Erlosamide) is a medication developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. |
中文名 | 拉克酰胺 |
---|---|
英文名 | (2R)-2-acetamido-N-benzyl-3-methoxypropanamide |
中文别名 | 拉科酰胺 | 拉考沙胺 | (R)-2-乙酰胺基-N-苄基-3-甲氧基丙酰胺 |
英文别名 | 更多 |
密度 | 1.1±0.1 g/cm3 |
---|---|
沸点 | 536.4±50.0 °C at 760 mmHg |
熔点 | 141-143?C |
分子式 | C13H18N2O3 |
分子量 | 250.294 |
闪点 | 278.2±30.1 °C |
精确质量 | 250.131744 |
PSA | 67.43000 |
LogP | 0.90 |
外观性状 | 固体 |
蒸汽压 | 0.0±1.4 mmHg at 25°C |
折射率 | 1.520 |
储存条件 | -20°C,干燥,密封 |
符号 |
GHS02, GHS07 |
---|---|
信号词 | Danger |
危害声明 | H225-H302 + H312 + H332-H319 |
警示性声明 | P210-P280-P305 + P351 + P338 |
危害码 (欧洲) | F,Xn |
风险声明 (欧洲) | 11-20/21/22-36 |
安全声明 (欧洲) | 16-26-36/37 |
危险品运输编码 | UN 1648 3 / PGII |
WGK德国 | 2.0 |
Molecule of the month. Lacosamide.
Drug News Perspect. 17(10) , 689, (2004)
|
|
SPM-927 (Schwarz Pharma).
IDrugs 6(5) , 479-85, (2003) Schwarz Pharma, under license from Harris FRC, is developing SPM-927, synthesized by researchers at the University of Houston, for the potential treatment of epilepsy and neuropathic pain. |
|
Does SPM 927 have an analgesic effect in human neuropathic pain? An open label study.
Neurosci. Lett. 352(2) , 117-20, (2003) The aim of the study is to establish if the putative anticonvulsant SPM 927 has an analgesic effect in human neuropathic pain and to assess its tolerability. This is an open label study of 25 adult hu... |
Vimpat |
Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)- |
Harkoseride |
Erlosamide |
Lacosamide |
UNII-563KS2PQY5 |
SPM 927 |
N-Acetyl-N-benzyl-O-methyl-D-serinamide |
S1253_Selleck |